Allan M. Johansen

Allan M. Johansen

Auto-generated profile, based on publicly available information

Allan M. Johansen

Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
AJAllan M. Johansen
Allan M. Johansen
Steven ForsytheSteven Forsythe
Steven Forsythe
CMCallum T. McGrath
Callum T. McGrath
GBGrayson Barker
Grayson Barker
HJHugo Jimenez
Hugo Jimenez
BPBoris C. Pasche
Boris C. Pasche
TGFβ is a pleiotropic signaling pathway that plays a pivotal role in regulating a multitude of cellular functions. TGFβ has a dual role in cell regulation where it induces growth inhibition and cell death; however, it can switch to a growth-promoting state under cancerous conditions. TGFβ is upregulated in colorectal cancer and pancreatic cancer, altering the tumor microenvironment and immune system and promoting a mesenchymal state. The upregulation of TGFβ in certain cancers leads to resistance to immunotherapy, and attempts to inhibit TGFβ expression have led to reduced therapeutic resistance when combined with chemotherapy and immunotherapy. Here, we review the current TGFβ inhibitor drugs in clinical trials for pancreatic and colorectal cancer, with the goal of uncovering advances in improving clinical efficacy for TGFβ combinational treatments in patients. Furthermore, we discuss the relevance of alterations in TGFβ signaling and germline variants in the context of personalizing treatment for patients who show lack of response to current therapeutics.

19 July 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
KAKojo Agyemang
Kojo Agyemang
AJAllan M. Johansen
Allan M. Johansen
GBGrayson W. Barker
Grayson W. Barker
MPMichael J. Pennison
Michael J. Pennison
KSKimberly Sheffield
Kimberly Sheffield
BPBoris Pasche
Boris Pasche
There is growing evidence that germline mutations in certain genes influence cancer susceptibility, tumor evolution, as well as clinical outcomes. Identification of a disease-causing genetic variant enables testing and diagnosis of at-risk individuals. For breast cancer, several genes such as BRCA1, BRCA2, PALB2, ATM, and CHEK2 act as high- to moderate-penetrance cancer susceptibility genes. Genotyping of these genes informs genetic risk assessment and counseling, as well as treatment and management decisions in the case of high-penetrance genes. TGFBR1*6A (rs11466445) is a common variant of the TGF-β receptor type I (TGFBR1) that has a global minor allelic frequency (MAF) of 0.051 according to the 1000 Genomes Project Consortium. It is emerging as a high frequency, low penetrance tumor susceptibility allele associated with increased cancer risk among several cancer types. The TGFBR1*6A allele has been associated with increased breast cancer risk in women, OR 1.15 (95% CI 1.01–1.31). Functionally, TGFBR1*6A promotes breast cancer cell proliferation, migration, and invasion through the regulation of the ERK pathway and Rho-GTP activation. This review discusses current findings on the genetic, functional, and mechanistic associations between TGFBR1*6A and breast cancer risk and proposes future directions as it relates to genetic association studies and mechanisms of action for tumor growth, metastasis, and immune suppression.

26 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
KAKojo Agyemang
Kojo Agyemang
AJAllan Johansen
Allan Johansen
GBGrayson Barker
Grayson Barker
MPMichael Pennison
Michael Pennison
HJHugo Jimenez
Hugo Jimenez
BPBoris Pasche
Boris Pasche
TGFBR1*6A (rs1466445) is a common low penetrance tumor susceptibility allele with a minor allelic frequency of 0.051. Several meta-analyses show that TGFBR1*6A is associated with breast cancer risk with an OR ranging from 1.15 to 1.30. We developed a novel knockin mouse model of TGFBR1*6A to study mammary cancer development and progression in MMTVneu mice. Here we show that TGFBR1*6A accelerates tumor onset, increases the percentage of mice with tumors, and the percentage of mice with multiple tumors. Age at tumor onset, tumor formation, and tumor multiplicity depend on TGFBR1*6A allelic dosage. Functional characterization shows that TGFBR1*6A confers higher tumor growth and clonogenicity and enhances G0/G1 cell cycle progression through downregulation of p27. These findings establish TGFBR1*6A as a potent modifier of breast cancer development and progression, which may affect more than 10% of patients with breast cancer.

1 January 2026 in Cancer Communications
Verified
Journal Article
Open access
AJAllan M. Johansen
Allan M. Johansen
JZJulie T. Ziegler
Julie T. Ziegler
KAKojo Agyemang
Kojo Agyemang
MPMichael J. Pennison
Michael J. Pennison
HJHugo Jimenez
Hugo Jimenez
BPBoris Claude Pasche
Boris Claude Pasche
It is estimated that 20% of 30% of colorectal cancer (CRC) cases are inherited, although the genetic drivers of risk are not well established [1]. Transforming growth factor beta (TGF-β) plays a central role in the development and progression of CRC. TGFBR1*6A (6A) is a common polymorphism of TGFBR1, an in-frame deletion of 3 GCG repeats coding for Alanine (Ala) within the TGFBR1 signal sequence. Wild-type TGFBR1 encodes for 9 Ala (9A) [2]. 6A (rs11466445) is not included in genome-wide association study (GWAS) chips and is commonly missed by next-generation sequencing platforms because of its high content of guanine (G) and cytosine (C) bases, which hamper polymerase chain reaction amplification by formation of secondary structures and the requirement for high melting temperatures. The association of 6A with cancer risk has been investigated in multiple types of cancer, and 6A is part of a haplotype putatively associated with colon cancer risk in humans [3]. The shortcoming of these studies has been the lack of adjustment for genetic ancestry and the investigation of a relatively low number of cases and controls. Here, we report the impact of 6A as a modifier of CRC using a novel knock-in mouse model and extend those findings to humans via a large family-based, case–control study, adjusting for genetic ancestry.